best online casino slots game
USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Dec. 20, 2024 /PRNewswire/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights , underscoring major strides in cancer research and ongoing innovation. However, the optimism is tempered by a troubling finding: a significant global rise in early-onset colorectal cancer cases . This unsettling trend comes as the medical community grapples with the lingering effects of the COVID-19 pandemic. A recent Nature article revealed how disruptions in cancer care—particularly delays in screenings, diagnoses, and treatments—have likely exacerbated the progression of advanced disease, diminished survival rates, and complicated long-term data analysis. Still, the oncology field continues to push forward with promising developments emerging from key innovators like O ncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cardiff Oncology, Inc. (NASDAQ: CRDF), Personalis, Inc. (NASDAQ: PSNL), Tempus AI, Inc. (NASDAQ: TEM), and Checkpoint Therapeutics, Inc. (NASDAQ: CKPT). The article continued: Additionally, the American Cancer Society has spotlighted an alarming rise in cancer incidence and mortality among younger age groups. Analysts at Exactitude Consultancy anticipate that the global Cancer Immunotherapy Market will expand at a robust 12.84% CAGR, reaching $258.22 billion by 2031 —a clear indicator of oncology's rapid growth and critical importance. Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers, which were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco January 23-25, 2025 . "We are enthusiastic about pelareorep's applicability across multiple gastrointestinal cancer indications, including pancreatic and anal cancer," said Tom Heineman , M.D., Ph.D., Chief Medical Officer of Oncolytics . "Pelareorep engages patients' immune systems to help make commonly used chemotherapies and checkpoint inhibitors, such as atezolizumab, more effective in fighting cancer. This offers the promise of delaying disease progression and improving survival in patients with these devasting diseases. Given the versatility of pelareorep, we see multiple clinical and regulatory options for bringing this promising medicine to patients." Oncolytics will present two key data sets from the GOBLET study, with preliminary safety and tumor response results for the relapsed anal carcinoma cohort treated with pelareorep and atezolizumab presented in Poster Session C on January 25, 2025 , from 7:00 to 7:55 a.m. PT . Additionally, results from the safety run-in phase for first-line metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep, modified FOLFIRINOX, with and without atezolizumab will be presented in Poster Session B on January 24, 2025 , from 11:30 a.m. to 1:00 p.m. PT . Both abstracts will be available on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025 . CONTINUED... Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ In other recent industry developments and happenings in the market include: Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, recently announced positive initial data from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). Efficacy and safety data are for all evaluable patients as of a November 26, 2024 , data cut-off date, and all efficacy data are determined by a blinded, independent central review (BICR) of each patient's tumor scan. "We are highly encouraged by the robust efficacy signal and favorable safety profile observed with onvansertib plus standard-of-care from the first 30 evaluable patients in our randomized first-line RAS-mutated mCRC CRDF-004 trial," said Fairooz Kabbinavar, MD, FACP, Chief Medical Officer of Cardiff Oncology . "Our data shows an objective response rate of 64% in patients receiving the 30 mg dose of onvansertib in combination with standard of care, significantly higher than the 33% objective response rate observed in the control arms of standard of care alone. In addition, as can be seen in the spider plots, we are observing deeper tumor response in patients receiving the 30mg dose of onvansertib compared to those receiving the 20mg dose with similar safety profiles for both doses." Personalis, Inc. (NASDAQ: PSNL), a developer of advanced cancer genomic tests and analytics, and Tempus AI, Inc. (NASDAQ: TEM), an AI-powered healthcare technology company, recently announced they've expanded their commercial relationship. Both companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis' ultra-sensitive tumor-informed MRD product, NeXT Personal® Dx, for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors. "While we already offer NeXT Personal through our own biopharma channel, we are pleased to leverage Tempus' integrated platform as well for these biopharma customers who desire to combine NeXT Personal with other Tempus products," said Chris Hall , CEO of Personalis . "We believe the expansion of the relationship with Tempus will accelerate market penetration of our leading ultra-sensitive MRD platform and allow us to better capitalize on the opportunity." Under this expanded relationship, Tempus will be enabled to offer Personalis' NeXT Personal MRD product to pharmaceutical and biotech customers who wish to bundle MRD testing with other Tempus offerings in a given study. Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), a commercial-stage immunotherapy and targeted oncology company focused on novel treatments for patients with solid tumor cancers, recently announced that the FDA approved its UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication. "[This] FDA approval of UNLOXCYT – the first marketing approval for our company – is a significant milestone both for Checkpoint and for patients with advanced cSCC," said James Oliviero , President and CEO of Checkpoin t. "This approval marks Checkpoint's transformation to a commercial-stage company, with the opportunity to compete in a U.S. market estimated to exceed $1 billion annually, where we believe UNLOXCYT offers a differentiated treatment option versus available therapies by binding to PD-L1, rather than programmed death receptor-1 (PD-1), to release the inhibitory effects of PD-L1 on the anti-tumor immune response. Additionally, UNLOXCYT has demonstrated the ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC), another potential differentiating feature of the drug compared to existing marketed therapies for patients with cSCC." Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content: https://www.prnewswire.com/news-releases/oncology-advancements-accelerate-amid-rising-early-onset-cancer-diagnoses-302337555.html SOURCE USA News Group
Zayn Malik pays tribute to Liam Payne at first show since band mate's death
John Parker Romo made a 29-yard field goal to lift the Minnesota Vikings to a 30-27 overtime win against the host Chicago Bears on Sunday afternoon. Romo buried the game-winning kick in his third career game for Minnesota (9-2), which won its fourth game in a row. The score capped a 10-play, 68-yard drive for the Vikings after the Bears went three-and-out on the first overtime possession. Sam Darnold completed 22 of 34 passes for 330 yards and two touchdowns to lead the Vikings. Wideout Jordan Addison finished with eight catches for a career-high 162 yards and a touchdown. The overtime defeat spoiled an impressive performance from rookie quarterback Caleb Williams, who completed 32 of 47 passes for 340 yards and two touchdowns for Chicago (4-7). D.J. Moore had seven catches for 106 yards and a touchdown, and Keenan Allen finished with nine catches for 86 yards and a score. Chicago erased an 11-point deficit in the final 22 seconds of regulation to send the game to overtime. Romo had put Minnesota on top 27-16 when he made a 26-yard field goal with 1:56 remaining in the fourth quarter. Williams trimmed the Bears' deficit to 27-24 with 22 seconds to go. He rolled right and found Allen wide open in the end zone for a 1-yard touchdown, and moments later he fired a strike to Moore for a two-point conversion. The Bears recovered an onside kick on the next play to regain possession at their 43-yard line with 21 seconds left. Cairo Santos' onside kick bounced off the foot of Vikings tight end Johnny Mundt, and Tarvarius Moore recovered it. D.J. Moore put the Bears in field-goal position with a 27-yard reception across the middle of the field, and Santos made a 48-yarder as time expired to even the score at 27-all. Minnesota led 24-10 after three quarters. Romo made a 40-yard field goal early in the third quarter, and Aaron Jones punched in a 2-yard run with 1:22 left in the period to put the Vikings on top by two touchdowns. Addison and Jalen Nailor each had receiving touchdowns in the first half for Minnesota. Roschon Johnson scored on a 1-yard run for the Bears' only touchdown of the first half. Chicago trailed 14-10 at the break. --Field Level MediaSwiss National Bank decreased its holdings in WillScot Mobile Mini Holdings Corp. ( NASDAQ:WSC – Free Report ) by 1.2% in the third quarter, HoldingsChannel reports. The institutional investor owned 369,193 shares of the company’s stock after selling 4,500 shares during the period. Swiss National Bank’s holdings in WillScot Mobile Mini were worth $13,882,000 at the end of the most recent reporting period. A number of other hedge funds also recently made changes to their positions in the business. V Square Quantitative Management LLC bought a new stake in shares of WillScot Mobile Mini in the 3rd quarter worth about $25,000. Hexagon Capital Partners LLC grew its holdings in shares of WillScot Mobile Mini by 200.0% in the 3rd quarter. Hexagon Capital Partners LLC now owns 900 shares of the company’s stock worth $34,000 after purchasing an additional 600 shares during the last quarter. Financial Management Professionals Inc. bought a new stake in shares of WillScot Mobile Mini in the 3rd quarter worth about $36,000. Summit Securities Group LLC bought a new stake in shares of WillScot Mobile Mini in the 2nd quarter worth about $56,000. Finally, CWM LLC grew its holdings in shares of WillScot Mobile Mini by 80.3% in the 2nd quarter. CWM LLC now owns 1,635 shares of the company’s stock worth $62,000 after purchasing an additional 728 shares during the last quarter. Institutional investors and hedge funds own 95.81% of the company’s stock. Analyst Ratings Changes Several research firms have recently weighed in on WSC. Oppenheimer lowered their target price on shares of WillScot Mobile Mini from $53.00 to $46.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Barclays lowered their target price on shares of WillScot Mobile Mini from $44.00 to $40.00 and set an “equal weight” rating on the stock in a report on Friday, November 1st. DA Davidson decreased their price objective on shares of WillScot Mobile Mini from $54.00 to $47.00 and set a “buy” rating on the stock in a report on Monday, August 5th. Bank of America decreased their price objective on shares of WillScot Mobile Mini from $56.00 to $54.00 and set a “buy” rating on the stock in a report on Friday, August 2nd. Finally, Baird R W lowered shares of WillScot Mobile Mini from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $45.00. WillScot Mobile Mini Stock Up 2.4 % Shares of NASDAQ WSC opened at $36.30 on Friday. The firm has a market capitalization of $6.71 billion, a PE ratio of 330.00, a price-to-earnings-growth ratio of 2.12 and a beta of 1.37. The company has a current ratio of 0.90, a quick ratio of 0.82 and a debt-to-equity ratio of 3.42. WillScot Mobile Mini Holdings Corp. has a 1 year low of $32.71 and a 1 year high of $52.16. The firm’s 50-day moving average is $37.68 and its 200-day moving average is $38.15. WillScot Mobile Mini ( NASDAQ:WSC – Get Free Report ) last issued its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.48 by ($0.10). The business had revenue of $601.43 million during the quarter, compared to the consensus estimate of $617.83 million. WillScot Mobile Mini had a net margin of 1.05% and a return on equity of 23.97%. The firm’s revenue for the quarter was down .6% compared to the same quarter last year. During the same period last year, the business posted $0.46 EPS. Equities analysts expect that WillScot Mobile Mini Holdings Corp. will post 1.53 EPS for the current year. Insider Activity In other news, CEO Bradley Lee Soultz purchased 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The shares were acquired at an average cost of $36.38 per share, for a total transaction of $181,900.00. Following the transaction, the chief executive officer now directly owns 144,686 shares of the company’s stock, valued at approximately $5,263,676.68. The trade was a 3.58 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link . Also, CAO Sally J. Shanks sold 14,059 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $34.69, for a total transaction of $487,706.71. Following the completion of the sale, the chief accounting officer now owns 26,113 shares in the company, valued at $905,859.97. This represents a 35.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here . In the last quarter, insiders have acquired 20,000 shares of company stock valued at $728,750. 3.30% of the stock is currently owned by insiders. WillScot Mobile Mini Company Profile ( Free Report ) WillScot Holdings Corporation provides workspace and portable storage solutions in the United States, Canada, and Mexico. It operates in two segments, Modular Solutions and Storage Solutions. Its modular solutions include panelized and stackable offices, single-wide modular space units, section modulars and redi-plex, classrooms, ground level offices, blast-resistant modules, clearspan structures, and other modular space; and portable storage solutions, such as portable and cold storage containers, as well as trailers. See Also Want to see what other hedge funds are holding WSC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for WillScot Mobile Mini Holdings Corp. ( NASDAQ:WSC – Free Report ). Receive News & Ratings for WillScot Mobile Mini Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WillScot Mobile Mini and related companies with MarketBeat.com's FREE daily email newsletter .
CARY, N.C. , Dec. 12, 2024 /PRNewswire/ -- Fathom Realty , a subsidiary of Fathom Holdings, Inc. (Nasdaq: FTHM) ("Fathom"; or the "Company "), a national, technology-driven, end-to-end real estate services platform integrating residential brokerage, mortgage, title, and SaaS offerings for brokerages and agents, has appointed Andrew Shock as Vice President of Operations. With over 20 years of experience in the residential brokerage industry, Shock brings a wealth of expertise and leadership to his new role, further strengthening Fathom Realty's operational capabilities. "Andrew's expertise, knowledge, and positive energy align perfectly with our vision and will drive us toward our goals," said Samantha Giuggio , President of Fathom Realty and Chief Operations Officer of Fathom Holdings. "With his leadership, we are confident in our continued journey to becoming the top choice for agents and clients in the country." Shock brings extensive real estate expertise spanning operational management, transactions across residential and commercial properties, corporate portfolio sales, and new home developments. As former Director of Operations at eXp Realty, he has demonstrated a track record of driving growth and operational excellence. His commitment to delivering exceptional results and creating value for clients and stakeholders makes him a valuable addition to the Fathom Realty team. Shock's operational oversight will allow DeJane Kerr , Senior Vice President of Compliance, to focus on brokerage compliance. This organizational change reflects Fathom Realty's commitment to driving growth and enhancing efficiency. "I'm honored to join Fathom and work with such a talented team," added Shock. "Throughout my career, I've been driven by a commitment to revolutionizing real estate, and Fathom's values strongly reflect that vision. Together, we're creating a platform where agents can grow, thrive, and achieve lasting success in a supportive environment." Shock earned two bachelor's degrees from the University of Toledo : one in Business Administration with a focus on Organizational Leadership and Management and another in Legal and Paralegal Studies. About Fathom Holdings Inc. Fathom Holdings Inc. is a national, technology-driven real estate services platform integrating residential brokerage, mortgage, title, and SaaS offerings to brokerages and agents by leveraging its proprietary cloud-based software, intelliAgent. The Company's brands include Fathom Realty, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. For more information, visit www.FathomInc.com . Cautionary Note Concerning Forward-Looking Statements This press release contains "forward-looking statements" that involve risks and uncertainties which we expect will or may occur in the future and may impact our business, financial condition and results of operations. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including risks associated with general economic conditions, including rising interest rates; its ability to generate positive operational cash flow; risks associated with the Company's ability to continue achieving significant growth; its ability to continue its growth trajectory while achieving profitability over time; risks related to ongoing and future litigation; and other risks as set forth in the Risk Factors section of the Company's most recent Form 10-K as filed with the SEC and supplemented from time to time in other Company filings made with the SEC. Copies of Fathom's Form 10-K and other SEC filings are available on the SEC's website, www.sec.gov . The Company undertakes no obligation to update these statements for revisions or changes after the date of this release except as required by law. Investor Contact: Matt Glover and Clay Liolios Gateway Group, Inc. 949-574-3860 FTHM@gateway-grp.com View original content to download multimedia: https://www.prnewswire.com/news-releases/fathom-realty-names-andrew-shock-vice-president-of-operations-to-drive-growth-and-innovation-302330711.html SOURCE Fathom Holdings Inc.None
LONDON (AP) — Edinburgh Airport was shut down by an unspecified information technology issue Sunday afternoon, causing headaches for passengers at the start of the busy holiday travel season. All flights into and out of Scotland’s busiest airport were grounded at 4:15 p.m. local time, with some incoming flights diverted to Glasgow Airport about 50 miles away. Edinburgh airport said engineers were working to resolve the issue. “Passengers are asked to check the status of their flight with the airline they are flying with before traveling to the airport,’’ the airport said in a statement.
Penguin who swam from Antarctica to Australia released back into sea
- Previous: 8gaming slot
- Next: best slot online games
